Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Duration in PPROM
NCT01503606Phase 3Completed
- Sponsor
- Samsung Medical Center
- Start
- Oct 2011
- Primary completion
- Dec 2020
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of cefazolin, clarithromycin in preterm premature rupture of membranes (pPROM), sponsored by Samsung Medical Center. Started Oct 2011; status: completed.
02
Drugs
cefazolinclarithromycin
03
Conditions
preterm premature rupture of membranes (pPROM)
Beyond the preview
Go deeper on NCT01503606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01503606.